Eckhard Scheufler, director of forecasting EMEA, Janssen-Cilag, on the rewards of building an integrated global forecasting system
Nikhil Gokhale, business planning manager at Actelion, and Robert Sigmund, Actelion’s director of commercial analytics, on the three principles of integrated forecasting models
Milos Graonic, senior vice president, global leader of Nielsen BASES Pharmaceutical Practice, on how to mine patient data for forecasting insights
Todd Johnson of Kantar Health outlines how market research can be honed into reliable data to improve forecasts
Angelo DePalma explores how many pharma firms are focusing on improved molecules, or biobetters, to optimize existing portfolios and increase market share
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharma forecasting
Angelo DePalma examines the commercial future of the biosimilars market
Angelo DePalma explores how drug firms can re-invent the pharma supply chain to add value to drug developers and benefit for patients
Craig DeLarge examines how pharma can capitalize on yet another new media trend.
Though the Internet is not quite a mass medium yet, Brazilians are very open to interacting with brands via social media
Paul Cook, analytics consultant with Blue Latitude, on the impact of the EU’s privacy directive on digital marketing and sales tracking
Will Myddelton, user experience consultant with Blue Latitude, on the human side of behavior change
When US marketing as a whole is becoming saturated, the Hispanic community offers potential growth
Why pharma marketing is like directing a feature film
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
Miriam Stache, senior European demand forecasting manager at Eli Lilly, on how integrated teams can provide more reliable forecasts
Prasad Saraph, business partner at Bayer HealthCare, explains why forecasting must reflect an organization’s collective intelligence
Peter Mansell reports on how to balance complexity and predictability when forecasting for biologics